Beyond Air posts record quarterly revenue, awaits FDA decision on next-gen LungFit PH
The company reported $2.3 million in quarterly revenue and reaffirmed 2026 and 2027 guidance while its PMA supplement for a second-generation device remains under FDA review.
Beyond Air, Inc. reported financial results for the quarter ended September 30, 2026, in a release dated November 11, 2026. The PMA supplement for the second-generation LungFit PH system, submitted in June 2025, remains under FDA review.1 CEO Robert Goodman said the company remains encouraged by active and productive discussions with the FDA and expects to complete its audit-readiness process in mid-December, subject to FDA inspections and final approval thereafter.1
The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground.1 The company said that if approved, the addition of transport capability would let it serve as a single-source nitric oxide provider for hospitals and health systems.1
On other pipeline items, Beyond Air said it received FDA Breakthrough Device Designation for LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD).1 However, the company said it will hold off on further work on LungFit GO until the second-generation LungFit PH launch is established post-approval, as stated in the release. Separately, Beyond Air announced a definitive agreement under which UNIVO Pharmaceutical Industries Ltd. would acquire the company's controlling interest in NeuroNOS Israel Ltd., a deal intended to give NeuroNOS dedicated resources, funding and strategic focus for its development programs.1 The company also said it is weighing possible partnership or other strategic options for Beyond Cancer's pipeline while keeping its own resources focused on commercializing LungFit PH.
Revenue for the quarter was $2.3 million, compared with $1.8 million for the same period last year.1 The company reaffirmed revenue guidance of $8 million for calendar year 2026, excluding second-generation revenue, and $16 million to $18 million for calendar year 2027, which includes anticipated second-generation revenue pending FDA approval.1
As of September 30, 2026, the company reported cash, cash equivalents, restricted cash and marketable securities of $18.5 million, including $2.7 million held by NeuroNos and $0.7 million held by Beyond Cancer.1 The company is also transitioning its fiscal year end from March 31 to December 31, effective December 31, 2026, and expects to file a transition report on Form 10-K/T for the nine-month period ending that date.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.